12:00 AM
 | 
Aug 06, 2012
 |  BC Week In Review  |  Company News  |  Deals

Oncobiologics, Xoma deal

Oncobiologics and Xoma partnered to develop biotherapeutics based on engineering single chain variable fragments (scFy) into a bi-specific antibody scaffold for cancer and immunology. Oncobiologics...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >